Ghost Tree Capital’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Ghost Tree Capital’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-125,000	Closed	-$580K	–	86
2017 Q2	$580K	Hold	125,000	–	–	0.12%	66
2017 Q1	$619K	Sell	125,000 -240,000	-66%	-$2.31M	0.12%	62
2016 Q4	$4.05M	Buy	365,000 +207,038	+131%	+$1.95M	0.98%	40
2016 Q3	$1.46M	Buy	+157,962	New	+$1.32M	0.24%	75
2015 Q4	–	Sell	-150,000	Closed	-$1.1M	–	79
2015 Q3	$1.1M	Sell	150,000 -100,000	-40%	-$1.02M	0.5%	57
2015 Q2	$2.56M	Buy	+250,000	New	+$2.76M	0.83%	47

Other funds holding FOMX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ghost Tree Capital's FOMX Position: Q3 2017 in Review

Ghost Tree Capital sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2017, closing a stake of 125,000 shares — an estimated $580K sold.

Ghost Tree Capital first reported a position in FOMX in Q2 2015 and held it in 6 quarters. The position peaked at $4.05M in Q4 2016. 45 funds tracked by Wall St. Rank hold FOMX as of Q3 2017.

Ghost Tree Capital reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Ghost Tree Capital sold 125,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2017, an estimated $580K.
Ghost Tree Capital first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 6 quarters.
Ghost Tree Capital's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $4.05M in Q4 2016.
45 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2017.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.